Therapeutics Company Announces Positive Trial Results For Fibro-inflammatory Disease Treatment

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or "the Company"), a clinical-stage biotechnology company focused on developing innovative treatments for fibro-inflammatory diseases with high unmet needs, recently announced substantial progress in its Phase 2 clinical trial for CM-101. The trial has demonstrated positive results in achieving primary and secondary endpoints, showing anti-fibrotic, anti-inflammatory, and anti-cholestatic effects in patients suffering from Primary Sclerosing Cholangitis (PSC). $Chemomab Therapeutics(CMMB.US)$